结直肠癌多药耐药逆转的研究进展  

Research progress in reversing multidrug resistance in colorectal cancer

作　　者：王熙 吴川清 Wang Xi;Wu Chuanqing(Department of Gastrointestinal Surgery,Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院胃肠外科,武汉430022

出　　处：《国际肿瘤学杂志》2023年第1期42-46,共5页Journal of International Oncology

摘　　要：结直肠癌的化疗疗效和预后受到多药耐药现象的影响。针对多药耐药发生的常见环节,包括ATP结合盒蛋白、代谢酶、细胞凋亡基因、信号通路及遗传物质等,目前已有诸多研究尝试研发相对应的抑制剂以克服耐药问题,其中P-糖蛋白抑制剂和破坏DNA复制修复药物的开发较为成熟。开发新的耐药靶点抑制剂,或探究已有耐药靶点抑制剂与传统治疗方案联用,是克服结直肠癌耐药的突破点。Multidrug resistance impacts negatively upon the curative effect of chemotherapy and prognosis in colorectal cancer.There is a growing body of studies trying to develop drugs to overcome multidrug resistance against its common targets,including ATP-binding cassette proteins,metabolic enzymes,apoptotic genes,signaling pathways and genetic material,among which P-glycoprotein inhibitors and drugs disrupting DNA are deeply developed.Developing new inhibitors or combining existing inhibitors with conventional treatment are hopeful ways to overcome multidrug resistance in colorectal cancer.

关 键 词：结直肠肿瘤 抗药性 肿瘤 

分 类 号：R735.34[医药卫生—肿瘤]